ArticleACS omega2026
Synthesis and Biological Evaluation of a New Family of STAT3 Inhibitors by a Diversity Oriented Approach Based on the Ugi-Multicomponent Reaction.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STAT3 (Signal Transducer and Activator of Transcription 3) is a protein frequently hyperactivated in a wide range of tumors, and as such, it has emerged as a promising and relatively recent therapeutic target for the development of novel anticancer agents. In this framework, we have designed and synthesized a new family of STAT3 inhibitors using a diversity-oriented strategy centered on the Ugi multicomponent reaction, enabling rapid access to structurally varied molecular scaffolds. We subsequently evaluated their antiproliferative activity across eight different tumor cell lines, revealing that four of the 23 newly obtained compounds exhibit pharmacologically meaningful growth-inhibitory effects within the micromolar range of concentrations and displayed promising drug-like profiles. Taken together, these findings highlight the potential of our approach to generate effective STAT3-modulating chemotypes and underscore the value of multicomponent reactions in accelerating early-stage anticancer drug discovery.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.